Literature DB >> 16626504

The fragile X syndrome: exploring its molecular basis and seeking a treatment.

Barbara Bardoni1, Laetitia Davidovic, Mounia Bensaid, Edouard W Khandjian.   

Abstract

Fragile X syndrome (FXS) - the leading cause of inherited mental retardation - is an X-linked disease caused by loss of expression of the FMR1 (fragile X mental retardation 1) gene. In addition to impairment of higher-cognitive functions, FXS patients show a variety of physical and other mental abnormalities. FMRP, the protein encoded by the FMR1 gene, is thought to play a key role in translation, trafficking and targeting of mRNA in neurons. To better understand FMRP's functions, the protein partners and mRNA targets that interact with FMRP have been sought. These and functional studies have revealed links with processes such as cytoskeleton remodelling via the RhoGTPase pathway and mRNA processing via the RNA interference pathway. In this review, we focus on recent insights into the function of FMRP and speculate on how the absence of FMRP might cause the clinical phenotypes seen in FXS patients. Finally, we explore potential therapies for FXS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16626504     DOI: 10.1017/S1462399406010751

Source DB:  PubMed          Journal:  Expert Rev Mol Med        ISSN: 1462-3994            Impact factor:   5.600


  32 in total

1.  A STEP forward in neural function and degeneration.

Authors:  Matthew L Baum; Pradeep Kurup; Jian Xu; Paul J Lombroso
Journal:  Commun Integr Biol       Date:  2010-09

2.  The fragile X mental retardation protein interacts with a distinct mRNA nuclear export factor NXF2.

Authors:  Dongmei Lai; Denny Sakkas; Yingqun Huang
Journal:  RNA       Date:  2006-06-21       Impact factor: 4.942

3.  Dendritic mRNA targeting of Jacob and N-methyl-d-aspartate-induced nuclear translocation after calpain-mediated proteolysis.

Authors:  Stefan Kindler; Daniela C Dieterich; Janin Schütt; Jale Sahin; Anna Karpova; Marina Mikhaylova; Claudia Schob; Eckart D Gundelfinger; Hans-Jürgen Kreienkamp; Michael R Kreutz
Journal:  J Biol Chem       Date:  2009-07-16       Impact factor: 5.157

Review 4.  Global signatures of protein and mRNA expression levels.

Authors:  Raquel de Sousa Abreu; Luiz O Penalva; Edward M Marcotte; Christine Vogel
Journal:  Mol Biosyst       Date:  2009-10-01

5.  Regulation of GABAA receptors by fragile X mental retardation protein.

Authors:  Baosong Liu; Lijun Li; Juan Chen; Zefen Wang; Zhiqiang Li; Qi Wan
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2013-09-10

6.  A study of the ultrastructure of fragile-X-related proteins.

Authors:  Ljiljana Sjekloća; Petr V Konarev; John Eccleston; Ian A Taylor; Dmitri I Svergun; Annalisa Pastore
Journal:  Biochem J       Date:  2009-04-15       Impact factor: 3.857

7.  Longitudinal in vivo developmental changes of metabolites in the hippocampus of Fmr1 knockout mice.

Authors:  Da Shi; Su Xu; Jaylyn Waddell; Susanna Scafidi; Steven Roys; Rao P Gullapalli; Mary C McKenna
Journal:  J Neurochem       Date:  2012-11-07       Impact factor: 5.372

8.  Differential expression of Fmr-1 mRNA and FMRP in female mice brain during aging.

Authors:  Kanchan Singh; S Prasad
Journal:  Mol Biol Rep       Date:  2007-09-27       Impact factor: 2.316

9.  Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice.

Authors:  Femke M S de Vrij; Josien Levenga; Herma C van der Linde; Sebastiaan K Koekkoek; Chris I De Zeeuw; David L Nelson; Ben A Oostra; Rob Willemsen
Journal:  Neurobiol Dis       Date:  2008-04-25       Impact factor: 5.996

10.  A mouse model of the human Fragile X syndrome I304N mutation.

Authors:  Julie B Zang; Elena D Nosyreva; Corinne M Spencer; Lenora J Volk; Kiran Musunuru; Ru Zhong; Elizabeth F Stone; Lisa A Yuva-Paylor; Kimberly M Huber; Richard Paylor; Jennifer C Darnell; Robert B Darnell
Journal:  PLoS Genet       Date:  2009-12-11       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.